Fabtech Technologies Limited has announced its financial results for the first and second quarters of fiscal year 2026, showing a significant turnaround from Q1 to Q2. The company has scheduled an earnings conference call to discuss its performance.

Q1 FY26 Financial Results

For the quarter ended June 30, 2025 (Q1 FY26), Fabtech Technologies reported:

• Net loss of ₹63.13 lakhs, compared to a net profit of ₹759.75 lakhs in the corresponding quarter of the previous year
• Revenue from operations of ₹3,012.65 lakhs, down from ₹2,506.10 lakhs year-over-year
• Basic earnings per share (EPS) turned negative at ₹2.83, compared to positive ₹3.70 in the same quarter last year

Q2 FY26 Financial Highlights

H1 FY26 Performance

• Revenue: ₹18,948.75 lakhs
• Net Profit: ₹2,198.02 lakhs

Recent Developments

• Completed IPO of 1,20,60,000 equity shares at ₹191 per share
• Listed on NSE and BSE on October 7, 2025
• Reported an exceptional item of ₹177.49 lakhs from sale of 51% stake in a subsidiary LLP

Earnings Call Details

Management Speakers

• Mr. Ashwani Kumar Singh, Chief Executive Officer
• Mr. Aman Anavkar, Chief Growth Officer

Participation Information

New Contract Announcement

On November 3, 2025, Fabtech Technologies Limited secured a significant contract:

• Contract Value: ₹52.00 crore
• Project: Construction of a next-generation veterinary formulations facility in North Africa
• Scope: Complete design, engineering, cleanroom systems, utilities, and process equipment

This contract has increased Fabtech's order book to ₹983.05 crore, enhancing revenue visibility and international presence.

Market Outlook

The company highlighted growth potential in the Maghreb region:

• Increasing demand for livestock and companion animal health products
• Growing focus on animal health management and disease prevention
• Projected veterinary formulation Total Addressable Market (TAM) in the Maghreb region: USD 500-700 million by 2030

Investors and interested parties are encouraged to participate in the upcoming earnings call for more detailed insights into Fabtech Technologies' financial performance and future outlook.

Note: Forward-looking statements made during the call are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

Fabtech Technologies Limited (FTL), a global turnkey solutions provider for the life sciences and healthcare sectors, has announced a significant expansion of its international operations. The company has secured a ₹52 crore contract to establish a state-of-the-art veterinary medicines manufacturing facility in the Maghreb region of North Africa.

Project Details

The scope of this ambitious project encompasses:

• Complete design and engineering
• Cleanroom systems
• Utilities
• Process equipment for a modern veterinary dosage manufacturing plant

This comprehensive approach showcases FTL's capability to deliver end-to-end solutions in the pharmaceutical manufacturing sector.

Financial Impact

With the addition of this new contract, Fabtech Technologies has seen a substantial boost to its order book:

This increase in the order book not only enhances the company's revenue visibility but also reinforces its momentum in international markets.

Market Opportunity

The veterinary formulation market in the Maghreb region presents a significant opportunity for growth:

• Projected market size by 2030: USD 500-700 million
• Drivers of growth:
  • Increasing demand for livestock and companion animal health products
  • Food security goals in the region
  • Rising exports from North Africa

Strategic Implications

This contract signifies Fabtech Technologies' strategic expansion across both human and animal healthcare sectors. The company is leveraging its in-house capabilities in design, manufacturing, and automation to capitalize on the growing demand in the animal health management and disease prevention markets.

The Maghreb region's focus on improving animal health is creating substantial opportunities for FTL's turnkey solutions. This project may pave the way for future contracts and open new avenues for regional growth.

Company Outlook

Fabtech Technologies Limited appears well-positioned to benefit from the expanding veterinary formulation market in North Africa. By securing this contract, the company demonstrates its ability to tap into emerging markets and diversify its project portfolio.

As the demand for advanced pharmaceutical manufacturing facilities continues to grow globally, FTL's expertise in providing comprehensive solutions could be a key differentiator in winning future contracts.

Note: Investors should be aware that forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from those projected.